Literature DB >> 2171333

Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis.

D C Classen1, J P Burke, C D Ford, S Evershed, M R Aloia, J K Wilfahrt, J A Elliott.   

Abstract

PURPOSE: Streptococcal infection has increasingly become a problem in neutropenic patients. We report on an outbreak of Streptococcus mitis sepsis in six bone marrow transplant patients receiving oral antimicrobial prophylaxis. PATIENTS AND METHODS: We performed an epidemiologic study of all patients in our bone marrow transplant program from 1986 to 1988. The hospital and microbiology records for all patients were reviewed. All bone marrow patients were treated according to specified protocols, including an oral prophylactic antimicrobial regimen that was changed in late 1987 from vancomycin/polymyxin/tobramycin to norfloxacin. Identification, susceptibility testing, and whole cell protein analysis of streptococcal isolates were performed at the Reference and Antimicrobial Investigations Laboratories at the Centers for Disease Control.
RESULTS: We detected six cases of S. mitis sepsis among 21 patients undergoing bone marrow transplantation. No other concurrent pathogen was isolated from any patient at the time of the S. mitis bacteremia. Bacteremia developed within 72 hours of transplant in five of six patients and was associated with severe mucositis in four patients. An environmental study failed to reveal any common source for the outbreak, and whole cell protein analysis of all six S. mitis isolates revealed each to be distinct. Of 12 patients receiving oral vancomycin/polymyxin/tobramycin, one developed S. mitis bacteremia, versus five of nine patients receiving norfloxacin (p less than 0.03).
CONCLUSION: We believe S. mitis bacteremia is a potential complication of bone marrow transplantation and is associated with antimicrobial prophylaxis with norfloxacin, especially in the setting of mucositis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2171333     DOI: 10.1016/0002-9343(90)90373-l

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Antimicrobial susceptibility patterns among viridans group streptococcal isolates from infective endocarditis patients from 1971 to 1986 and 1994 to 2002.

Authors:  Rajesh M Prabhu; Kerryl E Piper; Larry M Baddour; James M Steckelberg; Walter R Wilson; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

2.  In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer.

Authors:  F Alcaide; M A Benítez; J Carratalà; F Gudiol; J Liñares; R Martín
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.

Authors:  E R Broun; J L Wheat; P H Kneebone; K Sundblad; R A Hromas; G Tricot
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis.

Authors:  R M Prabhu; K E Piper; M R Litzow; J M Steckelberg; R Patel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

5.  Prevention of viridans-group streptococcal septicemia in oncohematologic patients: a controlled comparative study on the effect of penicillin G and cotrimoxazole.

Authors:  H F Guiot; J W van der Meer; P J van den Broek; R Willemze; R van Furth
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

6.  Oral antimicrobial prophylaxis in bone marrow transplant recipients: randomized trial of ciprofloxacin versus ciprofloxacin-vancomycin.

Authors:  C D Ford; W Reilly; J Wood; D C Classen; J P Burke
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Evaluation of penicillin G in the prevention of streptococcal septicaemia in patients with acute myeloid leukaemia undergoing cytotoxic chemotherapy.

Authors:  P de Jong; M de Jong; E Kuijper; J van der Lelie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-10       Impact factor: 3.267

8.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.

Authors:  J Carratala; A Fernandez-Sevilla; F Tubau; M A Dominguez; F Gudiol
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

10.  Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin.

Authors:  P H McWhinney; S Patel; R A Whiley; J M Hardie; S H Gillespie; C C Kibbler
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.